Ensign Group (ENSG) Pulls Back As Investors Question Whether Its Premium Valuation Still Fits

Ensign Group (ENSG) has drawn investor attention after recent share moves, with the stock down about 3% over the past week while still showing a gain over the past month.

See our latest analysis for Ensign Group.

Over a longer window, Ensign Group’s share price has slipped over the past quarter and year to date, even though the 1 year total shareholder return of 21.77% and 5 year total shareholder return of 102.98% point to a strong longer run outcome.

If you are weighing Ensign Group against other opportunities in the sector, it can be useful to see how healthcare companies using AI are priced and growing through the 41 healthcare AI stocks

For Ensign Group, a short spell of weaker trading set against solid multi year shareholder returns raises a simple tension: is the stock now marking time while the business catches up, or has sentiment moved ahead of fundamentals?

Preferred P/E of 27x: Is it justified?

Ensign Group currently trades on a P/E of 27x, a level that sits above both its peer set and the broader US healthcare sector, even though the stock is only fractionally below some fair value estimates based on future cash flows.

The P/E multiple compares the current share price to earnings per share and is a simple way to see how much investors are paying for each dollar of current earnings. For a company like Ensign Group, which operates skilled nursing, senior living, and post acute care real estate, this measure often reflects what the market is willing to pay for its earnings profile and business model.

Here, the 27x P/E is higher than the peer average of 15.9x and also above the US healthcare industry average of 25.7x. This indicates that the market is assigning Ensign Group a premium relative to both immediate peers and the wider sector. The estimated fair P/E of 25.3x is also lower than the current 27x level, which points to a valuation that sits above where regression based fair value benchmarks suggest the multiple could trend over time.

Explore the SWS fair ratio for Ensign Group

Result: Price-to-Earnings of 27x (OVERVALUED)

However, Ensign Group’s premium P/E could face pressure if annual revenue or net income growth of about 10% to 13% slows, or if sector sentiment turns.

Find out about the key risks to this Ensign Group narrative.

Another view on Ensign Group’s value

While Ensign Group looks expensive on a 27x P/E against peers at 15.9x and the US healthcare average of 25.7x, our DCF model points to a share price that is only about 0.3% below an estimated fair value of $169.63. This suggests a far more neutral picture.

This contrast, with the market paying a premium multiple but the SWS DCF model indicating only a slight undervaluation, leaves an open question for investors: which signal should carry more weight when judging what to pay for Ensign Group today?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ensign Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this Ensign Group valuation picture feels mixed, do not wait on others to decide for you. Review the underlying data, weigh the positives, and see what stands out in the 4 key rewards

Looking for more Ensign Group sized opportunities?

If Ensign Group has caught your attention, do not stop there, broaden your watchlist with fresh ideas that match your risk appetite and income goals.

• Target steady compounding by checking companies that combine quality and value through the 47 high quality undervalued stocks
• Lock in potential income streams by reviewing businesses offering strong payouts in the 7 dividend fortresses
• Prioritise resilience by focusing on financially robust stocks with the solid balance sheet and fundamentals stocks screener (49 results)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com